A Phase 2 interventional study of levonorgestrel and ethinyl estradiol in Ovulation Suppression, sponsored by Agile Therapeutics. Completed at 11 sites in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-05.
Sponsored by Agile Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).
The primary objective was to evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs) containing 2 different doses of levonorgestrel (LNG) and 3 different doses of ethinyl estradiol (EE) during 3 consecutive cycles of administration of each treatment.
Agile Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.
Drug: levonorgestrel and ethinyl estradiol
Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.
Drug: levonorgestrel and ethinyl estradiol
Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.
Drug: levonorgestrel and ethinyl estradiol
Drug pages: Levonorgestrel · Ethinyl Estradiol
pregnancy prevention
Also known as: contraception, hormonal contraception, transdermal
Ovulation Suppression in Three Treatment Groups Over 3 Cycles
Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are: Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points. Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are available across any of the data collection points. Perfect compliance: If no patch has been off \>1 day and no more than 1 day has elapsed between patch changes. Verifiable compliance: is a cycle during which at least 1 study patch was applied and where LNG and EE measurements were available at each of the nominal data collection points of Days 8, 15, and 22, and all values were above the lower detection limit.
Time frame: 3 months
Cycle Control
The incidence of breakthrough bleeding (BTB) and/or spotting (S) episodes in Cycle 3 for ITT cycles. A BTB/S episode was defined as any number of days with BTB and/or BTS preceded and followed by at least 2 bleeding-free days.
Time frame: 3 months
Planned enrollment included: approximately 30 subjects in the AG200LE treatment group, 30 subjects in the AG200 treatment group and 20 to 30 subjects in the AG200 15 treatment group. Actual enrollment included: 45 subjects in the AG200 treatment group; 45 subjects in the AG200LE treatment group; and 33 subjects in the AG200-15 treatment group.
| Milestone | AG200LE Transdermal Contraceptive Delivery System | AG200 Transdermal Contraceptive Delivery System | AG200-15 Transdermal Contraceptive System |
|---|---|---|---|
| Started | 45 | 45 | 33 |
| Completed | 41 | 41 | 25 |
| Not completed | 4 | 4 | 8 |
Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are: Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points. Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are available across any of the data collection points. Perfect compliance: If no patch has been off \>1 day and no more than 1 day has elapsed between patch changes. Verifiable compliance: is a cycle during which at least 1 study patch was applied and where LNG and EE measurements were available at each of the nominal data collection points of Days 8, 15, and 22, and all values were above the lower detection limit.
| %of cycles with possible ovulation | AG200LE | AG200 | AG200-15 |
|---|---|---|---|
| ITT, perfect compliance | 36.5 | 20.7 | 11.5 |
| Complete progesterone, perfect compliance | 36.9 | 20.7 | 11.7 |
| ITT, verifiable compliance | 32.5 | 14.9 | 12.0 |
| Complete progesterone, verifiable compliance | 32.5 | 14.9 | 12.0 |
The incidence of breakthrough bleeding (BTB) and/or spotting (S) episodes in Cycle 3 for ITT cycles. A BTB/S episode was defined as any number of days with BTB and/or BTS preceded and followed by at least 2 bleeding-free days.
| number of episodes | AG200LE | AG200 | AG200-15 |
|---|---|---|---|
| Cycle Control | 0.29 ± 0.46 | 0.29 ± 0.46 | 0.15 ± 0.36 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AG200LE | 0/43 (0%) | 0/43 (0%) | 19/43 (44.2%) |
| AG200 | 0/44 (0%) | 0/44 (0%) | 29/44 (65.9%) |
| AG200-15 | 0/31 (0%) | 0/31 (0%) | 19/31 (61.3%) |
| Event | AG200LE | AG200 | AG200-15 |
|---|---|---|---|
| Infections and infestationsInfections and infestations | 4/43 | 2/44 | 6/31 |
| Reproductive system and breast disordersReproductive system and breast disorders | 3/43 | 6/44 | 6/31 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 4/43 | 6/44 | 6/31 |
| Gastrointestinal disordersGastrointestinal disorders | 2/43 | 6/44 | 5/31 |
| General disorders and administration site conditionsGeneral disorders | 2/43 | 5/44 | 5/31 |
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 5/43 | 6/44 | 4/31 |
| Nervous system disordersNervous system disorders | 1/43 | 5/44 | 3/31 |
| InvestigationsInvestigations | 2/43 | 3/44 | 1/31 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 0/43 | 3/44 | 1/31 |
| Renal and urinary disordersRenal and urinary disorders | 1/43 | 0/44 | 2/31 |
Safety Population
| Age, Categorical(Participants) | AG200LE Transdermal Contraceptive Delivery System | AG200 Transdermal Contraceptive Delivery System | AG200-15 Transdermal Contraceptive System | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 43 | 44 | 31 | 118 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | AG200LE Transdermal Contraceptive Delivery System | AG200 Transdermal Contraceptive Delivery System | AG200-15 Transdermal Contraceptive System | Total |
|---|---|---|---|---|
| Mean | 31.7 ± 7.4 | 31 ± 6.9 | 32.1 ± 7.8 | 31.6 ± 7.3 |
| Sex: Female, Male(Participants) | AG200LE Transdermal Contraceptive Delivery System | AG200 Transdermal Contraceptive Delivery System | AG200-15 Transdermal Contraceptive System | Total |
|---|---|---|---|---|
| Female | 43 | 44 | 31 | 118 |
| Male | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | AG200LE Transdermal Contraceptive Delivery System | AG200 Transdermal Contraceptive Delivery System | AG200-15 Transdermal Contraceptive System | Total |
|---|---|---|---|---|
| United States | 43 | 44 | 31 | 118 |
The record gives a start of Sep 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2018, 10 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol
Agile Therapeutics